Philadelphia, Pennsylvania--(Newsfile Corp. - November 21, 2024) - Grabar Law Office is investigating claims on behalf of MacroGenics, Inc. (NASDAQ: MGNX) shareholders.
If you have continuously held MacroGenics stock since before March 7, 2024, you can seek corporate reforms, the return of funds to the company, and potentially receive a court-approved incentive award-all at no cost to you. Visit https://grabarlaw.com/the-latest/macrogenics-shareholder-investigation/ or email Joshua Grabar at jgrabar@grabarlaw.com.
Why?
A recent securities fraud class action claims that MacroGenics, Inc., via certain officers and directors, made misleading statements about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. When the truth was revealed on May 9, 2024-that the drug was significantly more dangerous than previously represented-the company's stock price plummeted by 77.4%, dropping $11.36 per share, and causing substantial losses for investors and harm to the Company.
Your Rights as a Longer Term Shareholder:
If you are a shareholder MacroGenics who has held shares since prior to March 7, 2024, this investigation may allow you to:
- Seek corporate governance reforms.
- Help recover funds expended in the class action for the company.
- Seek acourt-approved incentive award at no cost to you whatsoever.
What You Should Do Now:
To learn more about your rights and explore your options, or to join at no cost to you whatsoever, visit: https://grabarlaw.com/the-latest/macrogenics-shareholder-investigation/. For immediate assistance, reach out to Joshua H. Grabar at jgrabar@grabarlaw.com or call 267-507-6085.
#MacroGenics #ShareholderRights #CorporateAccountability $MGNX #InvestorAlert
Attorney Advertising Disclaimer
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/230860
